BRCA1 is an essential mediator of vinorelbine‐induced apoptosis in mesothelioma

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Pathology

• Publication date

  2012-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/path.3979PMID 22190288
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.

  2011cited by this paper
• PARP inhibition induces BAX/BAK‐independent synthetic lethality of BRCA1‐deficient non‐small cell lung cancer

  2011cited by this paper
• Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

  2011cited by this paper
• Resistance to discodermolide, a microtubule-stabilizing agent and senescence inducer, is 4E-BP1–dependent

  2010cited by this paper
• Immunohistochemical expression of BRCA1 and lethal prostate cancer.

  2010cited by this paper
• Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer

  2010cited by this paper
• The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.

  2009cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer.

  2009cited by this paper
• BRCA1 and implications for response to chemotherapy in ovarian cancer.

  2009cited by this paper
• Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas

  2009cited by this paper
• Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway.

  2008cited by this paper
• Advances in the systemic therapy of malignant pleural mesothelioma

  2008cited by this paper
• Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients

  2008cited by this paper
• BRCA1: a new genomic marker for non-small-cell lung cancer.

  2008cited by this paper
• Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial

  2008cited by this paper
• BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy

  2007cited by this paper
• RLIP 76 Transports Vinorelbine and Mediates Drug Resistance in Non – Small Cell Lung Cancer

  2005cited by this paper
• BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study

  2005cited by this paper
• Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.

  2005cited by this paper
• RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer.

  2005cited by this paper
• Expression of Class III β-Tubulin Is Predictive of Patient Outcome in Patients with Non–Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy

  2005cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.

  2005cited by this paper
• BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.

  2004cited by this paper
• Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development.

  2004cited by this paper
• BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells

  2003cited by this paper
• Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

  2003cited by this paper
• BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.

  2003cited by this paper
• Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer

  2003cited by this paper
• BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents

  2001cited by this paper
• Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway

  2001cited by this paper
• Phase II study of vinorelbine in patients with malignant pleural mesothelioma.

  2000cited by this paper
• Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas

  1999cited by this paper
• ABCC 10 / MRP 7 is associated with vinorelbine resistance in non-small cell lung cancer

  year unknowncited by this paper

• A Study on the Usage of Medications that Interact with the BRCA1 and BRCA2 Genes along with their Efficacy and Side Effects, in the Treatment of Breast Cancer Mutations

  2023cites this paper
• Targeted Approaches to Treatment of Pleural Mesothelioma: A Review

  2023cites this paper
• Pleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement

  2023cites this paper
• What's Current and What's New in Mesothelioma?

  2022cites this paper
• Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial

  2022cites this paper
• BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms

  2022cites this paper
• Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology

  2022cites this paper
• Advances in drug treatments for mesothelioma

  2022cites this paper
• An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma

  2022cites this paper
• Fibrosis in Mesothelioma: Potential Role of Lysyl Oxidases

  2022cites this paper
• Promising Investigational New Drugs for Mesothelioma: What Is the Next Stage of the Treatment for Advanced Mesothelioma?

  2021cites this paper
• Malignant Pleural Mesothelioma Interactome with 364 Novel Protein-Protein Interactions

  2021cites this paper
• Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.

  2021cites this paper
• BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma

  2020influential citation
• Mesothelioma: is chemotherapy alone a thing of the past?

  2020cites this paper
• Unmet Needs and Future Outlook of Mesothelioma Management

  2019cites this paper
• Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma.

  2019cites this paper
• Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.

  2018cites this paper
• Treatment of BRCA 1 / 2-associated breast cancer and identification of mutation carriers among breast cancer patients

  2017cites this paper
• Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma

  2017cites this paper
• Treatment of BRCA1/2-associated breast cancer and identification of mutation carriers among breast cancer patients

  2017cites this paper
• A Novel BRCA1‐Associated Protein‐1 Isoform Affects Response of Mesothelioma Cells to Drugs Impairing BRCA1‐Mediated DNA Repair

  2017cites this paper
• Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors

  2017cites this paper
• The established and future biomarkers of malignant pleural mesothelioma.

  2015cites this paper
• Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.

  2015cites this paper
• Resistance to HSP90 inhibition involving loss of MCL1 addiction

  2015cites this paper
• miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma

  2015cites this paper
• Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies.

  2015cites this paper
• CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?

  2014cites this paper
• Activation of AKT/ERK confers non-small cell lung cancer cells resistance to vinorelbine.

  2014cites this paper
• Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.

  2014cites this paper
• Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.

  2014cites this paper
• Second-line treatment in malignant pleural mesothelioma: translating the evidence into clinical practice

  2014cites this paper
• PTEN Phosphatase – Independent Maintenance of Glandular Morphology in a Predictive Colorectal Cancer Model System 1

  2013cites this paper
• PTEN phosphatase-independent maintenance of glandular morphology in a predictive colorectal cancer model system.

  2013cites this paper
• PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1

  2013cites this paper
• NON-SMALL-CELL LUNG CANCER

  2012cites this paper